Mary Kay Fenton - 29 Apr 2024 Form 4 Insider Report for Cullinan Therapeutics, Inc. (CGEM)

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	CGEM	Stock Option (Right to Buy)	Award	$0	+200,000		$0.000000	200,000	29 Apr 2024	Common Stock	200,000	$27.12	Direct	F1

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Id	Content
F1	The option represents a right to purchase a total of 200,000 shares of the Issuer's Common Stock, 25% of which will become vested and exercisable on April 29, 2025, with the remaining shares vesting in equal monthly installments over the following three years thereafter, subject to the Reporting Person's continued employment with the Issuer on each such vesting date.